Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback